SCHEMBL6472379

SCHEMBL6472379

Cc1cc2c(cc1S(=O)(=O)C=C(Cl)Cl)C(C)(C)CCC2(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 13/20 0.49
RXRB P28702 8/20 0.49
RXRG P48443 8/20 0.49
CYP26A1 O43174 6/20 0.46
CYP26B1 Q9NR63 2/20 0.40
RARG P13631 5/20 0.38
RARA P10276 4/20 0.38
RARB P10826 4/20 0.38
MEN1 O00255 1/20 0.37
ABCB11 O95342 1/20 0.37
ESR1 P03372 1/20 0.37
PGR P06401 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD1 P21728 1/20 0.37
TBXA2R P21731 1/20 0.37
SLC6A2 P23975 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22838098 0.77 RXRA (0.52) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL6473308 0.76 CYP26B1 (0.47) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL6472599 0.71 RXRA (0.50) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL7622765 0.68 RXRA (0.48) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL7872153 0.67 RXRA (0.59) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL8894039 0.66 RXRA (1.00) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL7565233 0.66 RXRA (0.46) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL6472228 0.65 RXRA (0.47) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL6472234 0.65 RXRA (0.47) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL7878427 0.65 RARG (0.57) RXRARXRBRXRGCYP26A1CYP26B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921777-B2 Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-26 US disclosed
US-20030012803-A1 Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-01-16 US disclosed
US-6444709-B1 SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2002-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030012803-A1 Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them TYR, CYP1B1, MITF RXRA 935/4885RXRB 836/4885RXRG 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.